Related Experiment Video

Updated: Jun 25, 2025

An In Vitro System to Study Tumor Dormancy and the Switch to Metastatic Growth
09:14

An In Vitro System to Study Tumor Dormancy and the Switch to Metastatic Growth

Published on: August 11, 2011

15.9K

Advances in the molecular regulation mechanism of tumor dormancy and its therapeutic strategy

Yuan Wang1, Linlin Wang1, Yaojun Wei1

  • 1School of Life Sciences and Biopharmaceutics, Guangdong Pharmaceutical University, Guangzhou, 51006, People's Republic of China.

Discover Oncology
|May 25, 2024
PubMed

Insights

Tumor dormancy, a quiescent state of cancer cells, presents challenges for eradication. Understanding its biological features and molecular mechanisms is key to developing novel therapies for malignant tumors.

Area of Science:

  • Oncology
  • Cancer Biology
  • Molecular Mechanisms

Background:

  • Tumor dormancy is a critical biological characteristic of malignant cells.
  • The transition between quiescent and proliferative states in dormant tumor cells complicates eradication efforts.
  • Understanding tumor dormancy is vital for advancing cancer diagnosis and treatment.

Purpose of the Study:

  • To explore the biological features of tumor dormancy.
  • To elucidate the molecular mechanisms underlying tumor dormancy.
  • To highlight emerging therapeutic strategies targeting tumor dormancy.

Main Methods:

  • Literature review of biological features.
  • Analysis of molecular mechanisms.
  • Review of emerging therapeutic strategies.

Main Results:

  • Dormant tumor cells exhibit complex transitions between quiescence and proliferation.
  • Various molecular pathways regulate tumor dormancy.
  • Emerging therapies show promise for clinical application against malignant tumors.

Conclusions:

  • Understanding tumor dormancy mechanisms offers insights into diagnosis and treatment.
  • Targeting tumor dormancy presents innovative clinical potential.
  • Advancing the fight against malignant tumors requires a deeper comprehension of dormancy.
Keywords:
Cell cycle blockMalignant tumorsTherapeutic strategiesTumor dormancyTumor metastasis

More Related Videos

An In Vitro Dormancy Model of Estrogen-sensitive Breast Cancer in the Bone Marrow: A Tool for Molecular Mechanism Studies and Hypothesis Generation08:48

An In Vitro Dormancy Model of Estrogen-sensitive Breast Cancer in the Bone Marrow: A Tool for Molecular Mechanism Studies and Hypothesis Generation

Published on: June 30, 2015

8.2K
A Time-lapse, Label-free, Quantitative Phase Imaging Study of Dormant and Active Human Cancer Cells12:48

A Time-lapse, Label-free, Quantitative Phase Imaging Study of Dormant and Active Human Cancer Cells

Published on: February 16, 2018

7.4K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
4.9K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.6K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
515